This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barter, P.J. Search for Related Content PubMed PubMed Citation Articles by Barter, P.J. Related Collections Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1095.)
© 2005 American Heart Association, Inc.

Editorials

Antiatherogenic Properties of Fibrates

P.J. Barter

From The Heart Research Institute, Sydney, Australia.

Correspondence to Prof Philip Barter, The Heart Research Institute, 145 Missenden Road, Camperdown, NSW 2050, Australia. Email p.barter@hri.org.au

Key Words: fibrates • HDL • ABCA1 • LXR • macrophages

An extract of the first 250 words of the full text is provided, because this article has no abstract.

In an era dominated by the use of statins as agents to reduce cardiovascular risk, fibrates have been largely forgotten. This is despite a remarkably robust evidence base certifying to the cardioprotective effects of these agents. In the Helsinki Heart Study (HHS), a 5-year, double-blind, placebo-controlled trial of the effects of gemfibrozil in 4081 men aged 40 to 55 years who were free of clinically manifest CHD at entry to the study, there was a statistically significant 34% reduction in the incidence of total coronary events from 41.4 per 1000 in the placebo group to 27.3 per 1000 in the gemfibrozil group.¹ In the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT), a 5-year, double-blind, placebo-controlled trial with gemfibrozil in 2531 men with clinical CHD and low levels of both high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol, the primary end point (nonfatal myocardial infarction or death attributable to CHD) was reduced significantly by 22% from 21.7% in the placebo group to 17.3% in the gemfibrozil group.² Positive results have also been obtained in angiographic studies with gemfibrozil in the Lopid Coronary Angiography Trial,³ with bezafibrate in the Bezafibrate Coronary Atherosclerosis Intervention Trial⁴ and with fenofibrate in the Diabetes Atherosclerosis Intervention Study.⁵

See page 1193

The cardiovascular benefits of treatment with fibrates appear to be greatest in people with insulin resistance and other features of the metabolic syndrome. In the HHS, a baseline level of serum triglyceride >200 mg/dL or a HDL cholesterol <40 mg/dL or a BMI >26 identified . . . [Full Text of this Article]

Related Article:

Fenofibric Acid, an Active Form of Fenofibrate, Increases Apolipoprotein A-I–Mediated High-Density Lipoprotein Biogenesis by Enhancing Transcription of ATP-Binding Cassette Transporter A1 Gene in a Liver X Receptor–Dependent Manner

Reijiro Arakawa, Norimasa Tamehiro, Tomoko Nishimaki-Mogami, Kazumitsu Ueda, and Shinji Yokoyama
Arterioscler Thromb Vasc Biol 2005 25: 1193-1197. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				J. Gao, Y. Xu, Y. Yang, Y. Yang, Z. Zheng, W. Jiang, B. Hong, X. Yan, and S. Si Identification of Upregulators of Human ATP-Binding Cassette Transporter A1 via High-Throughput Screening of a Synthetic and Natural Compound Library J Biomol Screen, August 1, 2008; 13(7): 648 - 656. [Abstract] [PDF]

				2nd International Symposium on Triglycerides and HDL: Lipid abnormalities and their treatment Diabetes Care, November 1, 2005; 28(11): 2795 - 2802. [Full Text] [PDF]